Bentley Pharmaceuticals, Inc. to Present Results of Initial Phase II I

    Pharmaceutical Writers/Business Editors/Medical Editors

    EXETER, N.H.--(BUSINESS WIRE)--April 21, 2005--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe (the "Company"), today announced that it has recently completed its data analysis of its Phase II clinical trial in Ireland of its proprietary intranasal insulin. Bentley will report the results in an abstract, titled "Intranasal Insulin Administration in Type I Diabetic Patients Utilizing CPE-215 Technology" at the American Diabetes Association 65th Scientific Sessions, June 10-14, 2005, in San Diego, California. Bentley previously reported successful completion of the study at the end of 2004. Previous studies of the intranasal insulin development program were published in Diabetes Technology and Therapeutics, Vol. 7 (1): 124-130, 2005 and previously presented at the Diabetes Technology Society Meeting in October, 2004 in Philadelphia, Pennsylvania.

    Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.
    Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com.

    Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding Bentley's intranasal insulin program. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the timing and results of clinical trials, efficacy and safety of our products, the timing and nature of regulatory approvals, expanding generic and branded drug operations, changes in third-party reimbursement and government mandates which impact pharmaceutical pricing, development and commercialization of our products, competition from other manufacturers of generic and proprietary pharmaceuticals, intellectual property litigation, our relationships with our strategic partners, the unpredictability of patent protection, technological changes, the effects of economic conditions, risks associated with international operations, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.

--30--MW/ny*

CONTACT: Bentley Pharmaceuticals, Inc. Michael D. Price, 603-658-6100 www.bentleypharm.com or Investor Relations Contacts: Porter, Le Vay & Rose, Inc. Investor Relations: Linda Decker, 212-564-4700 Editorial: Jeff Myhre, 212-564-4700 Media Relations: Tom Gibson, 201-476-0322

KEYWORD: NEW HAMPSHIRE CALIFORNIA IRELAND INTERNATIONAL EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL TRADESHOW SOURCE: Bentley Pharmaceuticals, Inc.

Copyright Business Wire 2005